Review
Research progress of prostate health index in the diagnosis and treatment of prostate cancer
Tan Zhiyong, Fu Shi, Zuo Jieming, Wang Haifeng, Wang Jiansong
Published 2023-03-15
Cite as Chin J Urol, 2023, 44(3): 234-236. DOI: 10.3760/cma.j.cn112330-20220401-00157-1
Abstract
Despite the increasing number of patients was diagnosed with prostate cancer due to widespread cancer screening, PSA testing does not differentiate between lethal and slow-growing inert prostate cancers. This leads to a proportion of patients being over-diagnosed and consequently over-treated.The current study has found that PSA exists as a precursor to post-translational modification, and that [-2]proPSA originates only from the peripheral zone of the prostate. Furthermore, the study has shown that prostate health index (PHI) calculated from [-2]proPSA, fPSA, and PSA has a higher positive predictive value for prostate cancer, making it useful in the diagnosis of clinically significant prostate cancer. This article reviews the progress of research related to PHI in prostate cancer diagnosis and treatment.
Key words:
Prostatic neoplasms; Carcinoma; Prostate health index; Prostate-specific antigen; Diagnosis; Treatment
Contributor Information
Tan Zhiyong
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
Fu Shi
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
Zuo Jieming
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
Wang Haifeng
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
Wang Jiansong
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
，PHI对有临床意义前列腺癌的诊断效能优于tPSA、fPSA、PSAD等指标，有助于鉴别高危前列腺癌，减少不必要的前列腺穿刺[3,4,5]，目前PHI已被国内外各大指南批准用于前列腺癌早期诊断和预后评估。本文就近年来PHI在前列腺癌诊疗中的相关研究进展进行综述。
